{"id":125214,"date":"2015-08-01T15:59:39","date_gmt":"2015-08-01T15:59:39","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=125214"},"modified":"2015-08-01T15:59:39","modified_gmt":"2015-08-01T15:59:39","slug":"oms-un-vaccin-contra-ebola-s-a-dovedit-eficient-100-in-timpul-testelor-in-guineea","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=125214","title":{"rendered":"OMS: Un vaccin contra Ebola s-a dovedit eficient 100% \u00een timpul testelor, \u00een Guineea"},"content":{"rendered":"<p>\n<strong>Vaccinul VSV-ZEBOV, produs de Merck \u015fi NewLink Genetics, a fost testat pe aproximativ 4.000 de oameni care s-au aflat \u00een contact str\u00e2ns cu cazuri de Ebola confirmate \u015fi a dovedit c\u0103 poate oferi protec\u0163ie dup\u0103 zece zile de la administrare.<\/strong><\/p>\n<p>\n<strong>Rezultatele testului a fost descrise drept &#8220;remarcabile&#8221; de speciali\u015ftii OMS. &#8220;Credem c\u0103 lumea este pe punctul de a avea un vaccin contra Ebola eficace&#8221;, a spus Marie Paule Kieny, expert \u00een vaccinuri \u00een cadrul OMS, \u00eentr-o conferin\u0163\u0103 de pres\u0103 care a avut loc la Geneva, vineri.<\/strong><\/p>\n<p>\nVaccinul ar putea fi utilizat pentru a pune cap\u0103t celei mai grave epidemii de Ebola, care a ucis peste 11.200 de persoane \u00een Africa de Vest, de la izbucnirea ei, \u00een decembrie 2013.<\/p>\n<p>\nDirectorul general al OMS, Margaret Chan, a spus c\u0103 vaccinul, descris \u00eentr-un articol publicat \u00een revista de specialitate The Lancet, ar putea &#8220;schimba modul de abordare a actualei epidemii de Ebola \u015fi a viitoarelor epidemii&#8221;.<\/p>\n<p>\nThe Gavi Alliance, care cump\u0103r\u0103 cantit\u0103\u0163i mari de vaccinuri pentru \u0163\u0103rile s\u0103race, ce nu \u00ee\u015fi permit acest lucru, a anun\u0163at c\u0103 va sprijini financiar acest vaccin, dup\u0103 ce va fi aprobat. &#8220;Trebuie s\u0103 fim preg\u0103ti\u0163i s\u0103 ac\u0163ion\u0103m oriunde acest virus reprezint\u0103 o amenin\u0163are&#8221;, a spus \u015feful Gavi, Seth Berkley.<\/p>\n<p>\n<strong>Testele pentru acest vaccin au \u00eenceput \u00een Guineea, pe 23 martie, \u015fi au vizat aplicarea \u015fi evaluarea eficacit\u0103\u0163ii unei singure doze de VSV-ZEBOV, folosind strategia &#8220;imuniz\u0103rii inel&#8221;, respectiv persoanele aflate \u00een str\u00e2ns\u0103 leg\u0103tur\u0103 cu pacientul diagnosticat cu Ebola au fost imunizate, fie imediat, fie la o dat\u0103 mai \u00eendep\u0103rtat\u0103.<\/strong><\/p>\n<p>\nDe\u015fi datele au ar\u0103tat c\u0103 vaccinul ofer\u0103 un nivel foarte mare de protec\u0163ie persoanelor vaccinate imediat dup\u0103 contactul cu bolnavul, cercet\u0103torii au a\u015fteptat data de 26 iulie pentru a decide s\u0103 nu mai aplice strategia de &#8220;\u00eent\u00e2rziere&#8221;, \u00eentruc\u00e2t devenise clar c\u0103 am\u00e2narea vaccin\u0103rii implic\u0103 riscuri lipsite de etic\u0103 \u015fi inutile.<\/p>\n<p>\n<strong>\u00cen prezent, testele sunt \u00een desf\u0103\u015furare, to\u0163i participan\u0163ii primind vaccinul imediat dup\u0103 contactul cu bolnavul, \u015fi vor fi extinse \u015fi \u00een s\u00e2nul grupurilor cu v\u00e2rste cuprinse \u00eentre 13 &#8211; 17 ani, posibil \u015fi 6 &#8211; 12 ani, spune OMS.<\/strong><\/p>\n<p>\nVaccinul VSV-ZEBOV a fost ini\u0163ial dezvoltat de agen\u0163ia de s\u0103n\u0103tate public\u0103 din Canada, dup\u0103 care a fost preluat de NewLink Genetics, care s-a asociat cu Merck pentru a-l \u00eembun\u0103t\u0103\u0163i, produce \u015fi distribui.<\/p>\n<p style=\"text-align: center;\">\n<iframe loading=\"lazy\" allowfullscreen=\"\" frameborder=\"0\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/8Y5i7HENDoM\" width=\"560\"><\/iframe><\/p>\n<p>\nFebra hemoragic\u0103 Ebola este o maladie infec\u0163ioas\u0103 viral\u0103 sever\u0103, de cele mai multe ori mortal\u0103, provocat\u0103 de virusul Ebola. Este caracterizat\u0103 prin afec\u0163iuni hemoragice severe la oameni, primate \u015fi antilopele duiker, manifest\u00e2ndu-se \u00een focare epidemice \u00een Africa central\u0103 \u015fi de vest. Are o rat\u0103 de mortalitate de p\u00e2n\u0103 la 90% la om \u015fi se transmite prin contact direct (piele r\u0103nit\u0103, mucoase) cu s\u00e2ngele, organele, secre\u0163iile, lichidele biologice (urina, saliva, sperm\u0103 etc.) ale persoanelor infectate, precum \u015fi prin contact indirect, prin intermediul mediilor contaminate cu aceste lichide. Virusul Ebola a fost identificat pentru prima dat\u0103 \u00een 1976, \u00een dou\u0103 focare simultane &#8211; Nzara (Sudan) \u015fi Yambuku (Republica Democrat\u0103 Congo), acesta din urm\u0103 fiind situat \u00een apropiere de r\u00e2ul Ebola, care a dat numele bolii.<\/p>\n<p>\n\u00cen prezent, nu exist\u0103 \u00eenc\u0103 nici un medicament specific disponibil \u00eempotriva febrei hemoragice Ebola, dar sunt disponibile tratamente poten\u0163iale, inclusiv produse din s\u00e2nge, terapii imunitare \u015fi medicamentoase \u00een curs de evaluare.<\/p>\n<p>\n<a name=\"14477700!\"><\/a><\/p>\n<p>\n&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un vaccin contra virusului febrei hemoragice Ebola, care a provocat peste 11.000 de decese \u00een Africa de vest din decembrie 2013, s-a dovedit a fi eficient 100% \u00een timpul testelor realizate \u00een Guineea, potrivit Organiza\u0163iei Mondiale a S\u0103n\u0103t\u0103\u0163ii (OMS), citat\u0103 de Reuters.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[37519,41248,14930],"class_list":["post-125214","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-ebola","tag-eficacitate","tag-vaccin"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/125214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=125214"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/125214\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=125214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=125214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=125214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}